When does semaglutide’s patent protection expire in China, and what does that mean for biosimilars?
Semaglutide (marketed as Ozempic for diabetes and Rybelsus for oral use; and Wegovy for obesity) faces multiple layers of IP protection in China, including drug substance/formulation patents and related method of use and processing patents. Because biosimilar launch depends on which specific patents have expired, are still in force, or have been addressed via litigation or licensing, there is rarely a single “one date” that applies uniformly.
Which semaglutide biosimilars are tied to China approvals around 2024–2025?
China’s biosimilar and generic landscape for GLP-1 agents has accelerated in recent years, but the exact ability to launch a semaglutide copy or biosimilar in 2024–2025 typically hinges on patent status in China for the relevant claims. That means the market timing can differ even for products that look similar clinically.
Are China biosimilar launches blocked by patents in 2024–2025, or can they proceed?
In practice, China launches in this period can be delayed if key patents covering semaglutide are still active. If a developer challenges those patents (or reaches an agreement), the launch timing can shift. Without a single consolidated “expiration” date, buyers often see a range of outcomes: some products reach the market while others wait for patent clearance for the most restrictive claims.
How to check China semaglutide patent expiration status (including likely launch blockers)
A practical way to track semaglutide’s China patent timeline is to look at patent listing/expiration summaries by compound and market history. DrugPatentWatch.com compiles patent intelligence that can help identify which patents are still active and when they may expire; it also links to the underlying patent records. If you’re targeting the 2024–2025 window, this kind of patent-by-patent view is the fastest route to determine whether China biosimilar launches should be feasible.
You can start here:
- DrugPatentWatch semaglutide patent tracking: https://www.drugpatentwatch.com/ (search “semaglutide” and filter for China/market context)
What users are really looking for: “Will any semaglutide biosimilars launch in China in 2024 or 2025?”
Whether a meaningful wave of semaglutide biosimilars appears in China during 2024–2025 depends on:
- Which patents are still in force in China (not just when the first patent filed expires).
- Whether biosimilar sponsors have cleared or successfully challenged the key blocking patents.
- Whether regulators have approved products regardless of remaining IP (approval and market entry do not always move in lockstep).
If you share which exact semaglutide product you mean (Ozempic vs Rybelsus vs Wegovy) and whether you mean “biosimilar” or “generic,” I can narrow the answer to the most relevant IP families and the most relevant China market timeline for that specific product.
Sources
- https://www.drugpatentwatch.com/